

Statement

Peania, Greece – [May 27, 2026]

Lavipharm S.A., announces the completion of the transaction for the acquisition of the commercialization rights and license trademarks of DUROGESIC® from Janssen Global Services LLC, announced on April 9, 2026, following unconditional clearance of the transaction by the competent Competition Authority.

About Lavipharm

Lavipharm (ASE: LAVI) is a pharmaceutical company focused on developing and delivering innovative healthcare solutions that advance patient care. Founded in Greece in 1911 and listed on the Athens Stock Exchange since 1995, the company has a strong presence in prescription and over-the-counter medicines in its domestic market. Lavipharm is internationally recognized for its expertise in transdermal drug delivery systems (TDDS) and maintains a global footprint through products distributed worldwide. With more than 115 years of history, Lavipharm remains committed to helping people live longer, healthier lives.

For further information contact:

Investor Relations:

Vasilis Baloumis

Tel: +30 210 6691 121

Email: ir@lavipharm.com